Vitetta ES - Search Results

1

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.

Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES. Stone MJ, et al. Among authors: vitetta es. Blood. 1996 Aug 15;88(4):1188-97. Blood. 1996. PMID: 8695836 Free article. Clinical Trial.

2

A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.

Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schön G, Bohlen H, Tesch H, Hansmann ML, Barth S, Schindler J, Ghetie V, Uhr J, Vitetta E. Engert A, et al. Blood. 1997 Jan 15;89(2):403-10. Blood. 1997. PMID: 9002941 Free article. Clinical Trial.

3

The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.

Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. Ghetie MA, et al. Among authors: vitetta es. Blood. 1992 Nov 1;80(9):2315-20. Blood. 1992. PMID: 1384801 Free article.

4

Phase I immunotoxin trial in patients with B-cell lymphoma.

Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, et al. Vitetta ES, et al. Cancer Res. 1991 Aug 1;51(15):4052-8. Cancer Res. 1991. PMID: 1855219 Clinical Trial.

5

Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest.

Ghetie MA, Picker LJ, Richardson JA, Tucker K, Uhr JW, Vitetta ES. Ghetie MA, et al. Among authors: vitetta es. Blood. 1994 Mar 1;83(5):1329-36. Blood. 1994. PMID: 7509655 Free article.

6

Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.

Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. Ghetie MA, et al. Among authors: vitetta es. Blood. 1994 Aug 1;84(3):702-7. Blood. 1994. PMID: 7519071 Free article.

7

A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.

Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA. Messmann RA, et al. Among authors: vitetta es. Clin Cancer Res. 2000 Apr;6(4):1302-13. Clin Cancer Res. 2000. PMID: 10778955 Clinical Trial.

8

A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.

Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S, Braunchweig I, Barta S, Ghetie V, Vitetta E, Verma A. Schindler J, et al. Br J Haematol. 2011 Aug;154(4):471-6. doi: 10.1111/j.1365-2141.2011.08762.x. Epub 2011 Jul 7. Br J Haematol. 2011. PMID: 21732928 Free PMC article. Clinical Trial.

9

Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.

Liu XY, Pop LM, Schindler J, Vitetta ES. Liu XY, et al. Among authors: vitetta es. MAbs. 2012 Jan-Feb;4(1):57-68. doi: 10.4161/mabs.4.1.18348. MAbs. 2012. PMID: 22327430 Free PMC article.

10

Immunotoxins in the therapy of cancer: from bench to clinic.

Ghetie V, Vitetta E. Ghetie V, et al. Pharmacol Ther. 1994 Sep;63(3):209-34. doi: 10.1016/0163-7258(94)90025-6. Pharmacol Ther. 1994. PMID: 7831391 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

434 results

Search Page

Filters